Journal profile · PHARMACOLOGY & PHARMACY
International Journal of Pharmaceutics-X
ISSN 2590-1567 · Elsevier · Netherlands · Continuous publication · Founded 2019
International Journal of Pharmaceutics-X: CAS Zone 2 · Medicine (2025 upgraded edition); impact factor 7.97; fully open access; APC about USD 2,660; median 72 days to acceptance (103 articles, last 24 months); 164 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
International Journal of Pharmaceutics-X is published by Elsevier and is in Zone 2 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Advanced Drug Delivery Systems, Drug Solubulity and Delivery Systems and Advancements in Transdermal Drug Delivery, together about 32.1% of its articles. Its main subfields are Pharmaceutical Science and Molecular Biology. (generated from OpenAlex topic counts and CAS ranking data)
International Journal of Pharmaceutics: X offers authors with high-quality research who want to publish in a gold open access journal the opportunity to make their work immediately, permanently, and freely accessible.International Journal of Pharmaceutics: X authors will pay an article publishing charge (APC), have a choice of license options, and retain copyright. Please check the APC here. The journal is indexed in SCOPUS, PUBMED, PMC and DOAJ.The International Journal of Pharmaceutics is the second most cited journal in the "Pharmacy & Pharmacology" category out of 358 journals, being the true home for pharmaceutical scientists concerned with the physical, chemical and biological properties of devices and delivery systems for drugs, vaccines and biologicals, including their design, manufacture and evaluation. This includes evaluation of the properties of drugs, excipients such as surfactants and polymers and novel materials. The journal has special sections on pharmaceutical nanotechnology and personalized medicines, and publishes research papers, reviews, commentaries and letters to the editor as well as special issues.Editorial Policy The over-riding criteria for publication are originality, high scientific quality and interest to a multidisciplinary audience. Papers not sufficiently substantiated by experimental detail will not be published. Any technical queries will be referred back to the author, although the Editors reserve the right to make alterations in the text without altering the technical content. Manuscripts submitted under multiple authorship are reviewed on the assumption that all listed authors concur with the submission and that a copy of the final manuscript has been approved by all authors and tacitly or explicitly by the responsible authorities in the laboratories where the work was carried out. If accepted, the manuscript shall not be published elsewhere in the same form, in either the same or another language, without the consent of the Editors and Publisher.Authors must state in a covering letter when submitting papers for publication the novelty embodied in their work or in the approach taken in their research. Routine bioequivalence studies are unlikely to find favour. No paper will be published which does not disclose fully the nature of the formulation used or details of materials which are key to the performance of a product, drug or excipient. Work which is predictable in outcome, for example the inclusion of another drug in a cyclodextrin to yield enhanced dissolution, will not be published unless it provides new insight into fundamental principles.
From the journal's Aims & Scope
Research area (LetPub): PHARMACOLOGY & PHARMACY
Editor-in-chief Juergen SiepmannPublisher website
Editorial board by country: 7 in mainland China (about 5%); most named United States 24, United Kingdom 21, Italy 14, Japan 9, Germany 8 (133 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Advanced Drug Delivery SystemsPharmacology, Toxicology and Pharmaceutics11.2%
- Drug Solubulity and Delivery SystemsPharmacology, Toxicology and Pharmaceutics10.9%
- Advancements in Transdermal Drug DeliveryPharmacology, Toxicology and Pharmaceutics10%
- Nanoparticle-Based Drug DeliveryMaterials Science9.6%
- Nanoplatforms for cancer theranosticsEngineering9.5%
- RNA Interference and Gene DeliveryBiochemistry, Genetics and Molecular Biology5.5%
- 3D Printing in Biomedical ResearchEngineering4.5%
- Protein purification and stabilityBiochemistry, Genetics and Molecular Biology3.3%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Pharmacology & Pharmacy | Zone 1 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Pharmacology & Pharmacy | Zone 2 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Pharmacology & Pharmacy | Zone 1 |
Top journal: noReview journal: no
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
PMCPubMedPublisher website
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 7.97LetPub ·
- Impact factor (publisher)
- 7.9Publisher website ·
- CiteScore 2026-06
- 8.9LetPub ·
- CiteScore (publisher)
- 8.9Publisher website ·
- SJR 2026-06
- 1.1LetPub ·
- SNIP 2026-06
- 1.46LetPub ·
- h-index
- 39OpenAlex ·
- i10-index
- 195OpenAlex ·
- 2-year mean citedness
- 3.58OpenAlex ·
- Self-citation rate
- 2.5%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 149LetPub ·
Articles by year OpenAlex count · 662 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 195 | 195 | 57 |
| 2025 | 164 | 164 | 517 |
| 2024 | 87 | 87 | 1,023 |
| 2023 | 67 | 67 | 1,234 |
| 2022 | 44 | 44 | 909 |
| 2021 | 38 | 38 | 865 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
72 daysMedian, submission to acceptance · P25–P75 54 days – 95 days
- Acceptance to online
- median 1 days (103 articles)
- Submission to online
- median 75 days
- Sample
- 103 articles with submission and acceptance dates (401 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 17 weeksLetPub ·
- Submission to first decision
- 2 daysPublisher website ·
- First decision after review
- 29 daysPublisher website ·
- Submission to acceptance
- 82 daysPublisher website ·
- Acceptance to publication
- 2 daysPublisher website ·
- Submission to publication (journal-reported)
- about 17 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 2,660 | Yes | CC BY, CC BY-NC, CC BY-NC-ND | |
| OpenAlex | USD 2,590 / EUR 2,420 / GBP 2,070 / JPY 321,240 | — | — | |
| LetPub | USD 2,790 | Yes | — | |
| Publisher website | USD 2,880 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Article types accepted4
- full length manuscriptsFull Length ManuscriptsLength not stated
- reviewFull Length ManuscriptsReviews and Mini-ReviewsSuggestions for review articles will be considered by the Review Editor. "Mini-reviews" of a topic are especially…Length not stated
- review articleFull Length ManuscriptsReviews and Mini-ReviewsSuggestions for review articles will be considered by the Review Editor. "Mini-reviews" of a topic are especially…Length not stated
- reviews and mini-reviewsReviews and Mini-Reviews Suggestions for review articles will be considered by the Review Editor. "Mini-reviews" of a topic are especially welcome.Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, License & copyright, Open access, Peer review, Preprints
- AI use Declaration of generative AI use
Authors must declare the use of generative AI tools in the manuscript preparation process upon submission of the paper.Generative AI and AI-assisted technologies (“AI tools”) have been rapidly adopted in research and scholarly publishing, offering significant benefits while requiring clear standards for responsible and transparent use.Authors preparing a manuscript for this journal may use AI tool…
Source ↗Publisher website ·- Authorship Group authorship
Group authorship refers to the attribution of an article to a defined and named group of authors whose members have contributed to the work. Examples include research consortia, clinical trial groups, collaborative networks, task forces or working groups, expert panels or consensus groups, and participatory research groups. Group authorship must be declared on the title page at submission. When av…
Source ↗Publisher website ·- Conflicts of interest Declaration of competing interests
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence or bias their work. Examples of potential competing interests include:EmploymentConsultanciesStock ownershipHonorariaPaid expert testimonyPatent applications or registrationsGrants or any other fundingAffiliation with the journal as an Editor or Advisory Board …
Source ↗Publisher website ·- License & copyright License options
Authors will be offered open access user license options which will determine how you, and third parties, can reuse your open access article. We advise that you review these options and any funding body license requirements before selecting a license option.
Source ↗Publisher website ·- Open access Open access
We refer you to our open access information page to learn about open access options for this journal.
Source ↗Publisher website ·- Peer review Peer review
single anonymized review process Model summary
This journal follows a single anonymized review process. Your submission will initially be assessed by our editors. If your submission is deemed suitable, it will typically be sent to be reviewed by a minimum of two reviewers for an independent expert assessment of the scientific quality. The decision as to whether your article is accepted or rejected for publication will be made by our editors.Re…
Source ↗Publisher website ·- Preprints Preprints
preprint sharing allowed Model summary
Preprint sharingAuthors may share preprints in line with Elsevier's article sharing policy. Sharing preprints, such as on a preprint server, will not count as prior publication.We advise you to read our policy on multiple, redundant or concurrent publication. In support of Open Science, this journal offers its authors a free preprint posting service on SSRN, Elsevier’s preprint and early research …
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Elsevier
- Country or region
- Netherlands
- Language
- English
- Frequency
- Continuous publication
- Founded
- 2019
- ISSN
- 2590-1567
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗Publisher website
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about International Journal of Pharmaceutics-X
What CAS zone is International Journal of Pharmaceutics-X in?
In the 2025 upgraded edition of the CAS Journal Ranking, International Journal of Pharmaceutics-X is in Zone 2 of Medicine, and in Zone 1 of the minor category Pharmacology & Pharmacy. In the 2026 Xinrui edition it is in Zone 2 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of International Journal of Pharmaceutics-X?
The latest impact factor listed by LetPub is 7.97; CiteScore 8.9, h-index 39.
How long does peer review take at International Journal of Pharmaceutics-X?
Based on the dates recorded on 103 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 72 days (interquartile range 54–95 days); authors report an average review time of about 17 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of International Journal of Pharmaceutics-X based?
Of the 133 board members whose country the journal's board page names, 7 (about 5%) are in mainland China; the countries named most often are United States (24), United Kingdom (21) and Italy (14). Counted from the institutions listed on the board page; for reference only.
Which databases index International Journal of Pharmaceutics-X?
According to LetPub and DOAJ records, International Journal of Pharmaceutics-X is indexed in SCIE, Scopus and DOAJ. The journal's website also lists PMC and PubMed; that list has not been checked against each database.
Is International Journal of Pharmaceutics-X open access, and what is the APC?
International Journal of Pharmaceutics-X is a fully open-access journal. APC about USD 2,660.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .